INTRODUCTION
Thank you for clicking through to find out about the research study we're asking you to participate in -- this study focuses on assessing whether practice patterns have changed since the initial survey was
conducted in preparation for ZEDS in 2010.
Please take a few minutes to complete this VERY short survey about HZO practice patterns. The study is being conducted by Drs. Elisabeth Cohen and Danielle Lo from NYU Langone Health in collaboration with ZEDS Study Co-Chair, Dr. Bennie Jeng. The study is titled: Update on Current Practice Patterns in Management of Recurrent or Chronic
Herpes Zoster Ophthalmicus.
Participation is entirely voluntary and involves simply completing this anonymous survey. While we are sending you individualized emails to encourage a sufficiently representative response, your actual responses will be stored without identifying information and will therefore be
anonymous. The individual responsible for tracking whether or not you have responded and sending reminders is not otherwise part of
ZEDS,and will not share any information on participation with the ZEDS team –thus, your decision to participate will be kept fully
confidential.
Practice Patterns in Managing HZO Survey
Whether or not you choose to participate will not be known to anyone on the ZEDS team and your decision cannot be linked to or affect your
employment or academic standing.
Risks associated with completing the survey are no more than one would anticipate in everyday life in the course of answering questions about clinical practices. Results from this study are expected to contribute to our understanding of current management of recurrent or chronic HZO.
You may also skip any questions you do not wish to answer or do not feel comfortable answering and you may stop participating at any time (simply by not completing/submitting the survey).
Completing the survey implies that you have provided consent to participating in this study. Should you have any questions about this study, please contact Principal Investigator Elisabeth Cohen at (215) 498-4434. If you have any questions, concerns, or complaints regarding your participation in this study or if you have any questions about your rights as a research subject and you would like to talk to someone other than those working on the study, you may contact the Institutional
Review Board at (212) 263-4110.
Thank you very much for taking the time to complete this survey to update our understanding of current HZO practice patterns and opinions among ZEDS investigators.
Sincerely,
PRACTICE PATTERNS - PATIENT X
For the purposes of this survey, oral antiviral treatment encompasses acyclovir, valacyclovir and famciclovir.
High dose, therapeutic treatment includes acyclovir 800 mg 5x a day, valacyclovir 1000 mg tid, and famiciclovir 500 mg tid.
Low dose, suppressive treatment includes acyclovir 800 mg bid, valacyclovir 1000 mg daily or 500 mg bid, and famciclovir 500 mg daily or 250 mg bid.
Patient X has a history of HZO with a typical rash treated with high dose antivirals for one week 3 months ago. Presents with blurry vision and photophobia and is found on exam to have active stromal keratitis with stromal infiltrates and edema, without an epithelial defect. Which of the following treatments would you most commonly prescribe for this patient? Please select all that apply.
Topical steroids
High dose oral antivirals Low dose oral antivirals None of the above
In the case of the above patient, if you choose to treat with oral antivirals, please indicate your initial choice of antiviral and dose (and then
interval/frequency of dose in the next question).
Acyclovir 800 mg Valacyclovir 500 mg Valacyclovir 1000 mg Famciclovir 250 mg Famciclovir 500 mg
OTHER
For the initial choice of oral antiviral identified above, please indicate the dosing frequency/interval:
Daily BID TID 5x/day
In the case of the above patient (Patient X), if you chose to treat with oral antivirals, which of the following treatment durations most closely parallels your practice patterns?
1-2 weeks One year
As long as topical steroids administered
In the case of Patient X, if you chose to administer oral antivirals, please comment on your antiviral protocol:
PRACTICE PATTERNS - PATIENT Y
Patient Y has a history of HZO with a typical rash treated with high dose antivirals for one week 2 years ago and has been stable on low dose topical steroids for one year. Presents with blurry vision and
photophobia and is found on exam to have active stromal keratitis with stromal infiltrates and edema, without an epithelial defect. Which of the following treatments would you most commonly prescribe for this patient? Please select all that apply
O H
Topical steroids
High dose oral antivirals Low dose oral antivirals None of the above
In the case of the above patient (Patient Y), if you choose to treat with oral antivirals, please indicate your initial choice of antiviral and dose (and then interval/frequency of dose in the next question).
For the initial choice of oral antiviral identified above, please indicate the dosing frequency/interval:
In the case of the above patient (Patient Y), if you chose to treat with oral antivirals, which of the following treatment durations most closely
parallels your practice patterns?
Acyclovir 800 mg Valacyclovir 500 mg Valacyclovir 1000 mg Famciclovir 250 mg Famciclovir 500 mg
OTHER
Daily BID TID 5x/day
1-2 weeks One year
As long as topical steroids administered
In the case of this patient (Patient Y), if you chose to administer oral antivirals, please comment on your antiviral protocol:
PRACTICE BELIEFS
Do you believe that prolonged suppressive antiviral treatment can prevent or reduce recurrent and/or chronic signs of HZO during the period of administration?
Comments or questions about prolonged suppressive antiviral treatment preventing or reducing recurrent and/or chronic signs of HZO during the period of administration:
O H
No Yes
I don't know
Do you believe prolonged suppressive antiviral treatment can prevent or reduce recurrent and/or chronic signs of HZO after the period of
administration?
Comments or questions about prolonged suppressive antiviral treatment preventing or reducing recurrent and/or chronic signs of HZO after the period of administration:
DEMOGRAPHICS
For how many years have you been in practice?
How would you characterize the setting of your practice?
No Yes
I don't know
Community private practice Academic/University
Where is your practice located in the U.S.?
How many cases of HZO do you estimate you have treated in the past year?
In the past year, what percent of the cases of HZO you have treated do you estimate have recurrent and/or chronic disease with HZO onset 6 or more months ago?
Additional comments?
O H
Northeast Southeast Midwest Southwest West
<20 20-49 50-99 100+
Powered by Qualtrics
